Rapid monitoring of biomarkers in postoperative care

Projektinformationen

MD

ID Finanzhilfevereinbarung: 673561

DOI 10.3030/673561

Projekt abgeschlossen

EK-Unterschriftsdatum 13 April 2015

Startdatum 1 Mai 2015

Enddatum 31 Oktober 2015

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

MD BIOMEDICAL AB
Sweden

Ziel

Colorectal cancer is the third most common cancer in the world, with nearly 1.4 million new cases diagnosed in 2012. The frequency of complications after surgery is relatively high, but rapid and safe monitoring methods are missing.

MD Biomedical AB has addressed this need and developed a radically new and innovative piece of medical equipment that is gently attached on the surface of the bowel for sampling of biomakers. This makes it possible to detect complications within minutes, at an early stage of illness, and long before patient systemic indications.

The possibility of rapid counteractions improves the treatment of the patient and save health care costs.

The feasibility study comprises one work package divided in 6 tasks and shall in measurable terms assess the functional, medical, economic, and environmental effects and the deliverable is a feasibility report including a business plan.

Wissenschaftliches Gebiet

• medical and health sciences › clinical medicine › surgery
• social sciences › economics and business › economics › monetary and finances
• medical and health sciences › clinical medicine › oncology › colorectal cancer
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › antibiotics

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Thema/Themen

• PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2014-2015

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2014

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

MD BIOMEDICAL AB

• Netto-EU-Beitrag: € 50 000,00
• Adresse: PO POX 7995 ; 90719 UMEA ; Schweden
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Norra Sverige › Övre Norrland › Västerbottens län
• Region: Norra Sverige › Övre Norrland › Västerbottens län
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00